

CLEANSING NOTICE

Perth, Australia; 3 AUGUST 2023 – Argenica Therapeutics Limited (ASX: AGN) (“**Argenica**” or the “**Company**”) confirms that it has issued 800,000 fully paid ordinary shares (Shares) pursuant to the exercise of 800,000 unlisted options with a \$0.30 exercise price and 6 August 2023 expiry date, raising \$240,000 (before costs). An Appendix 2A regarding the issue of these Shares has also been announced today.

Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001 (Cth) (“Act”)

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, the Shares noted in the Appendix 2A will fall within the exemption in section 708A(5) of the Act.

The Company advises that:

- a) The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- b) this notice is being given under sections 708A(5)(e) of the Corporations Act;
- c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act, as it applies to the Company; and
- d) as at the date of this notice, there is no information that is “excluded information” within the meanings of sections 708A(7) and 708A(8) of the Corporations Act.

This announcement was authorised for release by the Chairman and Managing Director of the Company.

Emma Waldon
Company Secretary

[ENDS]